Female Hormonal Balance & Libido Protocol

Address female hypoactive sexual desire disorder (HSDD) and hormonal dysregulation via central arousal pathways and HPG axis stimulation

Patient profile: Women with low libido, hormonal dysregulation, hypothalamic amenorrhoea, or perimenopausal sexual dysfunction; not suitable as monotherapy for oestrogen deficiency

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol →

⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

Kisspeptin-10

Primary

Dose

1–2 mcg/kg SC

Frequency

Pulsatile: every 90–120 min for 2–4 hours (2–3 pulses) OR 1x/day as simplified protocol

Timing

Evening preferred — aligns with LH pulsatility window

Duration

Weeks 1–8 (reassess at week 8 based on LH/FSH response)

PT-141 (Bremelanotide)

Supporting

Dose

0.5–1 mg

Frequency

As needed, max 1x/72 hours

Timing

45–60 min before sexual activity

Duration

As needed throughout protocol

Oxytocin (intranasal)

Optional

Dose

24 IU (4 puffs)

Frequency

As needed

Timing

15–30 min before intimacy — bonding and arousal facilitation

Duration

As needed throughout protocol

Monitoring Parameters

✓Female Sexual Function Index (FSFI) — baseline, week 6, week 12
✓LH, FSH, oestradiol, testosterone (free and total) — baseline and week 8
✓Prolactin — baseline (exclude as driver of low libido)
✓Blood pressure before PT-141 (mild transient increase expected)
✓Thyroid panel — baseline (rule out hypothyroidism as primary cause)

Expected Outcomes

Weeks 1–3: Improved mood, initial increase in desire frequency

Weeks 4–8: LH normalisation, improved arousal response, PT-141 working reliably

Weeks 9–12: Sustained libido improvement, improved FSFI score, improved relationship satisfaction

Contraindications

✗PCOS with existing LH excess — Kisspeptin may worsen LH/FSH ratio
✗Hormone-sensitive malignancies
✗Cardiovascular disease or uncontrolled hypertension (PT-141)
✗Pregnancy or active IVF cycle without medical supervision
✗Nausea-prone individuals — PT-141 commonly causes nausea; start at 0.5 mg

Clinical Notes

This protocol addresses two distinct axes: Kisspeptin targets the hypothalamic HPG axis (hormonal regulation, cycle normalisation), while PT-141 acts centrally on melanocortin receptors to increase sexual arousal directly. Oxytocin enhances bonding and arousal facilitation but does not affect hormonal status. For women whose low libido is primarily relationship-contextual or psychogenic, PT-141 alone may be sufficient. Kisspeptin should be dosed in pulsatile fashion — continuous dosing causes KISS1R desensitisation. Women on hormonal contraception may have blunted response to Kisspeptin due to suppression of endogenous HPG axis.

Case Study

Clinical Practice Example

Female, 36, 18 months postpartum. FSFI score 14.2/36 (severe dysfunction). Self-reported: absent desire, reduced arousal, relationship strain. Labs: LH 2.1 mIU/mL (low), FSH normal, testosterone free 1.2 pg/mL (below range), prolactin normal, thyroid normal. Protocol: Kisspeptin-10 1.5 mcg/kg SC evening (pulsatile 2x) 5 days/week + PT-141 0.5 mg as needed. Week 4: LH 5.8, free testosterone 3.1 pg/mL, FSFI improved to 21. PT-141 used 3x (mild nausea on first use, resolved). Week 12: FSFI 28.4, LH 7.2, free testosterone 5.4 pg/mL. Patient described outcome as 'life-changing'. Oxytocin not used — patient declined.

← Back to all protocols